BiOrion Technologies BV

BiOrion Technologies BV is a Netherlands-based **biopharmaceutical** company founded in **2003**. The company specializes in developing combined PET-imaging diagnostics and targeted radionuclide therapeutics (theranostics) for fibrotic diseases and fibrotic cancers. BiOrion has differentiated itself from other companies by focusing on fibrogenesis, the activity involved in the formation of fibrotic tissue, rather than the conventional approach of focusing on collagen deposition. Their development of high-affinity binding single domain antibodies to PDGF-beta-receptors has proven to be a sensitive biomarker for fibrogenesis, providing a more reliable parameter to assess fibrosis. This approach has led to the creation of attractive non-invasive PET imaging tools for diagnosing fibrogenesis, as well as for determining the effectiveness of antifibrotic therapies, ultimately expediting the novel antifibrotic therapies' development. The company's innovative technology is not limited to fibrotic diseases but also extends to metastasizing cancers that rely on fibrotic stroma with similar biology to organ fibrosis. BiOrion's utilization of 68Gallium-labeled single domain antibodies for PET imaging of PDGF beta receptor-rich stroma tissue presents an opportunity for diagnosing these cancers. Furthermore, the potential to replace 68Gallium with 177Lutetium allows for the use of the single domain antibody as a targeted radiotherapeutic, especially beneficial for advanced colon cancer metastases to the liver. With its novel approach and promising applications in both fibrotic diseases and metastasizing cancers, **BiOrion Technologies** demonstrates potential for significant impact in the **biotechnology** and **pharmaceutical** industries.